AngioDynamics is showing signs of a commercial turnaround with revenue growth reaccelerating to 8.0% in 2026Q4, yet this top-line momentum is insufficient to overcome a deeply unprofitable cost structure. The company's operating losses widened to -$20.4M in th...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 14, 2026 | -$0.07+36.4% vs -$0.11 | $87M+7.9% vs $80M |
Q2 2026 Apr 2, 2026 | -$0.07+36.4% vs -$0.11 | $78M+2.2% vs $77M |
Q1 2026 Jan 6, 2026 | -$0.15-50.0% vs -$0.10 | $79M+3.9% vs $76M |
Q4 2025 Oct 2, 2025 | -$0.10+28.6% vs -$0.14 | $76M-0.8% vs $76M |
Canada Pension Plan Investment Board purchased a new position in shares of AngioDynamics, Inc. (NASDAQ: ANGO) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 32,900 shares of the medical instruments supplier's stock, valued at approximately $428,000. Canada Pension Plan
Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 503,640 shares of the medical instruments supplier's stock after purchasing an additional 364,763
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.
Benchmark ANGO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AngioDynamics, Inc. (ANGO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.51 | $641.07M | -17.63 | 9.46% | -11.48% | -20.77% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $87.07 | $5.19B | 40.88 | 11.66% | 9.22% | 9.07% | — | |
| $126.32 | $4.29B | 43.71 | 7.57% | 6.97% | 7.43% | — | |
| $45.80 | $1.37B | 30.33 | 5.16% | 4.12% | 5.51% | — |
AngioDynamics, Inc. (ANGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
AngioDynamics, Inc. (ANGO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 14, 2026·SEC
Apr 23, 2026·SEC
Apr 2, 2026·SEC
Get notified when ANGO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AngioDynamics, Inc. (ANGO) stock FAQ — growth, dividends, profitability & financials explained
AngioDynamics, Inc. (ANGO) reported $320.2M in revenue for fiscal year 2026. This represents a 936% increase from $30.9M in 2002.
AngioDynamics, Inc. (ANGO) grew revenue by 9.5% over the past year. This is steady growth.
AngioDynamics, Inc. (ANGO) reported a net loss of $36.7M for fiscal year 2026.
AngioDynamics, Inc. (ANGO) has a return on equity (ROE) of -20.8%. Negative ROE indicates the company is unprofitable.
AngioDynamics, Inc. (ANGO) generated $0.5M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
